PASG

Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program

Retrieved on: 
Tuesday, March 5, 2024
PASG, Mentorship, University, Patient, Career, Science, Student, Nursing

Passage Bio will select one sophomore student annually to award $10,000 in scholarship funding – $5,000 over two consecutive years to be used toward college-related expenses.

Key Points: 
  • Passage Bio will select one sophomore student annually to award $10,000 in scholarship funding – $5,000 over two consecutive years to be used toward college-related expenses.
  • Passage Bio first announced its plans to launch the annual Tachi Yamada Scholarship Program in October 2021 to continue the legacy of Tadataka (Tachi) Yamada, M.D., a visionary biopharma industry leader who passed away in August 2021.
  • The official rules and application details are available on Passage Bio’s website in the Careers section at Passage Bio, Inc. – Careers .
  • Applications must be submitted by April 26, 2024 and will be evaluated by a panel of Passage Bio employees; the winner will be selected by Passage Bio at its discretion.

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

Retrieved on: 
Monday, March 4, 2024
GRN, Granulin, Interim management, Cohort, Senior, ALS, Alzheimer's disease, GM1, PASG, Research and development, Frontotemporal dementia, FTD, Interim, Safety, Immunosuppression, Administration, Patient, Clinical trial, CSF, Krabbe disease, Pharmaceutical industry

"In 2023, we achieved a significant milestone by announcing encouraging data from three patients in Cohort 1 of our FTD-GRN program.

Key Points: 
  • "In 2023, we achieved a significant milestone by announcing encouraging data from three patients in Cohort 1 of our FTD-GRN program.
  • We eagerly anticipate a catalyst-rich 2024, supported by our robust balance sheet, bringing us closer to improving patient outcomes across neurodegenerative diseases."
  • Additionally, Dose 1 of PBFT02 continued to be generally well-tolerated in patients who received an enhanced steroid regimen for immunosuppression.
  • Cash Position: Cash, cash equivalents and marketable securities were $114.3 million as of December 31, 2023, as compared to $189.6 million as of December 31, 2022.

Passage Bio to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, February 27, 2024
Patient, PASG

PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences:

Key Points: 
  • PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences:
    A live webcast of the panel discussion will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com .
  • A replay of the panel will be available for 30 days following the event.

Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Retrieved on: 
Wednesday, January 31, 2024
Biotechnology, Conference, PASG, Patient

PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 10:00 a.m.

Key Points: 
  • PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 10:00 a.m.
  • ET.
  • A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com .
  • A replay of the presentation will be available for 30 days following the event.

Terrell "TJ" Ray Williams- Ward Jr. Ushers in 2024: A Fusion of Football, Sports Entertainment, and Social Impact

Retrieved on: 
Tuesday, January 30, 2024
PASG, Multimedia, Culture, Athlete, Sport, Terron, SNG, NFL

Ward' s dedication to social impact extends beyond his exciting podcast venture.

Key Points: 
  • Ward' s dedication to social impact extends beyond his exciting podcast venture.
  • Through the Ward Boy Project, a 501 ( c) 3 non- profit organization he founded, T. J. is deeply committed to empowering young leaders and athletes.
  • His upcoming podcast and continuous work in social causes and sports management showcase his commitment to making a meaningful impact in every endeavor he undertakes.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/terrell-tj-ray-williams--ward-j...
    SOURCE Terrell "TJ" Ray Williams- Ward Jr.

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Retrieved on: 
Wednesday, December 20, 2023
CSF, Immunosuppression, Partnership, ALS, GM1, Aes, Krabbe disease, FTD, Loss, ICM, PASG, Clinical trial, Plasma, Inflammation, Methylprednisolone, AAV, Toxicity, GRN, Patient, Frontotemporal dementia, Safety, Cell biology, Hepatotoxicity, MLD, DRG, Pharmaceutical industry

Additionally, the company shared updated strategic priorities aimed at further optimizing its portfolio for the treatment of neurodegenerative conditions.

Key Points: 
  • Additionally, the company shared updated strategic priorities aimed at further optimizing its portfolio for the treatment of neurodegenerative conditions.
  • "We are proud to announce initial clinical data from our upliFT-D clinical trial, which showcases the ability of PBFT02 to elevate CSF progranulin to supraphysiologic levels at the lowest tested dose, Dose 1, up to six months post-treatment.
  • The upliFT-D clinical trial evaluates PBFT02 as a single dose delivered via intra-cisterna magna (ICM) injection.
  • These strategic priorities and clinical milestones underscore Passage Bio's dedication to advancing cutting-edge, one-time genetic medicines and protecting patients and families against loss in neurodegenerative conditions.

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
Friday, November 17, 2023
CNS, Central nervous system, Employment, PASG, Pharmaceutical industry

PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee.

Key Points: 
  • PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee.
  • Passage Bio granted options to purchase 10,400 shares of common stock to this employee as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock options have an exercise price of $0.628 per share, which is equal to the closing price of Passage Bio’s common stock on November 15, 2023, the grant date of the options.
  • The stock options have a 10-year term and are subject to the terms and conditions of the stock option agreement.

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Retrieved on: 
Monday, November 13, 2023
Infant, CNS, Research, Safety, PASG, GRN, Workforce, CSF, Clinical trial, Administration, Patient, FTD, G&A, Granulin, Dose, Frontotemporal dementia, Financial management, R, Research and development, Central nervous system, GM1, Pharmaceutical industry, Medical imaging

Robust balance sheet to support achievement of meaningful clinical milestones, with cash runway into Q4 2025

Key Points: 
  • Robust balance sheet to support achievement of meaningful clinical milestones, with cash runway into Q4 2025
    PHILADELPHIA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2023, and provided recent business highlights.
  • "Our team remains focused on execution, and this past quarter marked another stride toward achieving key milestones across our two lead clinical programs.
  • Initial data focused on safety and CSF progranulin levels from three Cohort 1 patients is expected in the fourth quarter of 2023.
  • Present initial safety and biomarker data from three Cohort 1 patients in upliFT-D clinical trial for FTD in Q4 2023.

Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference

Retrieved on: 
Monday, October 30, 2023
Conference, Inflammation, CNS, Central nervous system, PASG, Pharmaceutical industry, Broadcasting

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference on Monday, November 6, 2023 at 2:30 p.m.

Key Points: 
  • PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference on Monday, November 6, 2023 at 2:30 p.m.
  • ET.
  • A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com .
  • A replay of the presentation will be available for 30 days following the event.

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, October 20, 2023
CNS, Employment, Central nervous system, PASG, Pharmaceutical industry

PHILADELPHIA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to new employees.

Key Points: 
  • PHILADELPHIA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to new employees.
  • Passage Bio granted options to purchase 50,000 shares of common stock to these employees as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock options have an exercise price of $0.674 per share, which is equal to the closing price of Passage Bio’s common stock on October 16, 2023, the grant date of the options.
  • The stock options have a 10-year term and are subject to the terms and conditions of the stock option agreement.